Viatris Inc. (VTRS)

Market Cap	12.42B
Revenue (ttm)	15.36B
Net Income (ttm)	-56.10M
Shares Out	1.19B
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	3.74
Dividend	$0.48 (4.60%)
Ex-Dividend Date	May 23, 2024

Volume	4,835,950
Open	10.70
Previous Close	10.59
Day's Range	10.33 - 10.71
52-Week Range	8.74 - 13.62
Beta	0.97
Analysts	Sell
Price Target	11.00 (+5.47%)
Earnings Date	Aug 8, 2024

About VTRS

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agent...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Scott Andrew Smith
• Employees: 38,000
• Stock Exchange: NASDAQ
• Ticker Symbol: VTRS

Financial Performance

In 2023, Viatris's revenue was $15.43 billion, a decrease of -5.14% compared to the previous year's $16.26 billion. Earnings were $54.70 million, a decrease of -97.37%.

Analyst Forecast

According to 3 analysts, the average rating for VTRS stock is "Sell." The 12-month stock price forecast is $11.0, which is an increase of 5.47% from the latest price.

Price Target

$11.0

(5.47% upside)

Analyst Consensus: Sell